UCB enters gene therapy space, inking license agreement for epilepsy and neurodegeneration research
UCB may not have any gene therapy candidates on the market or publicly in its pipeline, but that hasn’t stopped the pharma from inking a multi-year license agreement with ClearPoint Neuro to work on drug delivery platforms for UCB’s gene therapy portfolio, according to the companies.
As part of the agreement, UCB will use ClearPoint Neuro’s tech and services to develop and commercialize UCB’s gene therapy products and ClearPoint will receive success-based milestone payments. More financial details of the agreement weren’t described.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.